- Home
- TNGX vs DCOMP Comparison
TNGX vs DCOMP Comparison
Compare TNGX & DCOMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- DCOMP
- Stock Information
- Founded
- TNGX 2014
- DCOMP N/A
- Country
- TNGX United States
- DCOMP United States
- Employees
- TNGX N/A
- DCOMP 887
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- DCOMP Major Banks
- Sector
- TNGX Health Care
- DCOMP Finance
- Exchange
- TNGX Nasdaq
- DCOMP Nasdaq
- Market Cap
- TNGX 351.2M
- DCOMP N/A
- IPO Year
- TNGX N/A
- DCOMP N/A
- Fundamental
- Price
- TNGX $6.01
- DCOMP $19.44
- Analyst Decision
- TNGX Strong Buy
- DCOMP
- Analyst Count
- TNGX 6
- DCOMP 0
- Target Price
- TNGX $12.20
- DCOMP N/A
- AVG Volume (30 Days)
- TNGX 2.7M
- DCOMP N/A
- Earning Date
- TNGX 08-06-2025
- DCOMP N/A
- Dividend Yield
- TNGX N/A
- DCOMP N/A
- EPS Growth
- TNGX N/A
- DCOMP N/A
- EPS
- TNGX N/A
- DCOMP N/A
- Revenue
- TNGX $40,990,000.00
- DCOMP N/A
- Revenue This Year
- TNGX N/A
- DCOMP N/A
- Revenue Next Year
- TNGX N/A
- DCOMP N/A
- P/E Ratio
- TNGX N/A
- DCOMP N/A
- Revenue Growth
- TNGX 10.09
- DCOMP N/A
- 52 Week Low
- TNGX $1.03
- DCOMP N/A
- 52 Week High
- TNGX $12.02
- DCOMP N/A
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- DCOMP 69.03
- Support Level
- TNGX $5.34
- DCOMP $19.03
- Resistance Level
- TNGX $6.40
- DCOMP $19.44
- Average True Range (ATR)
- TNGX 0.50
- DCOMP 0.40
- MACD
- TNGX -0.02
- DCOMP 0.13
- Stochastic Oscillator
- TNGX 84.08
- DCOMP 97.88
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About DCOMP Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.